Literature DB >> 21814188

The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

María Rodríguez-Muñoz1, Pilar Sánchez-Blázquez, Ana Vicente-Sánchez, Esther Berrocoso, Javier Garzón.   

Abstract

The capacity of opioids to alleviate inflammatory pain is negatively regulated by the glutamate-binding N-methyl-D-aspartate receptor (NMDAR). Increased activity of this receptor complicates the clinical use of opioids to treat persistent neuropathic pain. Immunohistochemical and ultrastructural studies have demonstrated the coexistence of both receptors within single neurons of the CNS, including those in the mesencephalic periaqueductal gray (PAG), a region that is implicated in the opioid control of nociception. We now report that mu-opioid receptors (MOR) and NMDAR NR1 subunits associate in the postsynaptic structures of PAG neurons. Morphine disrupts this complex by protein kinase-C (PKC)-mediated phosphorylation of the NR1 C1 segment and potentiates the NMDAR-CaMKII, pathway that is implicated in morphine tolerance. Inhibition of PKC, but not PKA or GRK2, restored the MOR-NR1 association and rescued the analgesic effect of morphine as well. The administration of N-methyl-D-aspartic acid separated the MOR-NR1 complex, increased MOR Ser phosphorylation, reduced the association of the MOR with G-proteins, and diminished the antinociceptive capacity of morphine. Inhibition of PKA, but not PKC, CaMKII, or GRK2, blocked these effects and preserved morphine antinociception. Thus, the opposing activities of the MOR and NMDAR in pain control affect their relation within neurons of structures such as the PAG. This finding could be exploited in developing bifunctional drugs that would act exclusively on those NMDARs associated with MORs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814188      PMCID: PMC3242298          DOI: 10.1038/npp.2011.155

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors.

Authors:  W Y Lu; Z G Xiong; S Lei; B A Orser; E Dudek; M D Browning; J F MacDonald
Journal:  Nat Neurosci       Date:  1999-04       Impact factor: 24.884

2.  Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors.

Authors:  Julie Perroy; Fabrice Raynaud; Vincent Homburger; Marie-Claude Rousset; Ludovic Telley; Joël Bockaert; Laurent Fagni
Journal:  J Biol Chem       Date:  2008-01-08       Impact factor: 5.157

3.  Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes.

Authors:  Silvia Marinelli; Christopher W Vaughan; Stephen A Schnell; Martin W Wessendorf; MacDonald J Christie
Journal:  J Neurosci       Date:  2002-12-15       Impact factor: 6.167

4.  RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-D-aspartate receptor-calmodulin-dependent protein kinase II pathway.

Authors:  Javier Garzón; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Concha Bailón; Ricardo Martínez-Murillo; Pilar Sánchez-Blázquez
Journal:  Antioxid Redox Signal       Date:  2011-05-19       Impact factor: 8.401

Review 5.  Ca2+-calmodulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains.

Authors:  B Chakravarthy; P Morley; J Whitfield
Journal:  Trends Neurosci       Date:  1999-01       Impact factor: 13.837

6.  Opioid enhancement of calcium oscillations and burst events involving NMDA receptors and L-type calcium channels in cultured hippocampal neurons.

Authors:  R Przewlocki; K L Parsons; D D Sweeney; C Trotter; J G Netzeband; G R Siggins; D L Gruol
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

7.  mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons.

Authors:  G Martin; Z Nie; G R Siggins
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

Review 8.  New therapy for neuropathic pain.

Authors:  Hirokazu Mizoguchi; Chizuko Watanabe; Akihiko Yonezawa; Shinobu Sakurada
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

9.  L-glutamate has higher affinity than other amino acids for [3H]-D-AP5 binding sites in rat brain membranes.

Authors:  H J Olverman; A W Jones; J C Watkins
Journal:  Nature       Date:  1984 Feb 2-8       Impact factor: 49.962

10.  Post-synaptic action of morphine on glutamatergic neuronal transmission related to the descending antinociceptive pathway in the rat thalamus.

Authors:  Minoru Narita; Keisuke Hashimoto; Taku Amano; Michiko Narita; Keiichi Niikura; Atsushi Nakamura; Tsutomu Suzuki
Journal:  J Neurochem       Date:  2008-01       Impact factor: 5.372

View more
  50 in total

Review 1.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Selective Role of RGS9-2 in Regulating Retrograde Synaptic Signaling of Indirect Pathway Medium Spiny Neurons in Dorsal Striatum.

Authors:  Chenghui Song; Garret R Anderson; Laurie P Sutton; Maria Dao; Kirill A Martemyanov
Journal:  J Neurosci       Date:  2018-07-13       Impact factor: 6.167

3.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

Review 4.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.

Authors:  Branden A Smeester; Mary M Lunzer; Eyup Akgün; Alvin J Beitz; Philip S Portoghese
Journal:  Eur J Pharmacol       Date:  2014-09-17       Impact factor: 4.432

6.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

7.  Hepatic encephalopathy induces site-specific changes in gene expression of GluN1 subunit of NMDA receptor in rat brain.

Authors:  Shamseddin Ahmadi; Mahsa Poureidi; Jalal Rostamzadeh
Journal:  Metab Brain Dis       Date:  2015-04-22       Impact factor: 3.584

8.  Endometriosis Is Associated With a Shift in MU Opioid and NMDA Receptor Expression in the Brain Periaqueductal Gray.

Authors:  Annelyn Torres-Reverón; Karylane Palermo; Anixa Hernández-López; Siomara Hernández; Myrella L Cruz; Kenira J Thompson; Idhaliz Flores; Caroline B Appleyard
Journal:  Reprod Sci       Date:  2016-04-18       Impact factor: 3.060

9.  Phosphorylation of the N-methyl-d-aspartate receptor is increased in the nucleus accumbens during both acute and extended morphine withdrawal.

Authors:  Ethan M Anderson; Turi Reeves; Katherine Kapernaros; John K Neubert; Robert M Caudle
Journal:  J Pharmacol Exp Ther       Date:  2015-09-16       Impact factor: 4.030

10.  Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Javier Garzón
Journal:  Antioxid Redox Signal       Date:  2013-06-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.